Fundraising FoxGenrAb
Dallas, US · Founded 2022 · Delaware corporation
Find your way into GenrAb
Sign up to see every warm intro you have to GenrAb
- Paths you didn't know you had: your email and LinkedIn already hold routes to the GenrAb team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
GenrAb develops neuroprotective therapies derived from the human immune system to treat neurological diseases including ALS, Parkinson's, Alzheimer's, and Multiple Sclerosis. The company addresses unmet needs in neurodegeneration treatment by harnessing immunological pathways to prevent disease progression.
Founders & leadership
GenrAb was founded in 2022 by Dr. Ben Greenberg and Dr. Nancy Monson.
DB
Dr. Ben GreenbergCEO/CMO
DN
Dr. Nancy MonsonCSO
RV
Richard VincentExecutive
LT
Larry TiffanyExecutive
Board
NW
Neil WarmaBoard director
DK
Doug KerrBoard director
Funding
SEC filings, press & company announcements$4.6M disclosed across 1 of 3 rounds · 2022–2025
- Undisclosed amountSeedApr 2025Source ↗
▶$4.6MraisedApr 2025 · 48 investors · Other Health CareRule 506(b)
▶$4.6MraisedApr 2025 · 48 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Neil WarmaDirector
- Richard VincentExecutive Officer
- Nancy MonsonExecutive Officer, Promoter
- Doug KerrDirector
- Larry TiffanyExecutive Officer, Director
- Benjamin GreenbergExecutive Officer
- Offering amount
- $5.9M
- Amount sold
- $4.6M
- Sales commissions
- $80K
- Placement agents
- Salem Partners LLC
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does GenrAb do?
- GenrAb develops neuroprotective therapies derived from the human immune system to treat neurological diseases including ALS, Parkinson's, Alzheimer's, and Multiple Sclerosis. The company addresses unmet needs in neurodegeneration treatment by harnessing immunological pathways to prevent disease progression.
- Who founded GenrAb?
- GenrAb was founded by Dr. Ben Greenberg, Dr. Nancy Monson in 2022.
- How much funding has GenrAb raised?
- GenrAb has disclosed $4.6M raised across 1 of its 3 known rounds.
- Where is GenrAb headquartered?
- GenrAb is headquartered in Dallas, US.